COCP on Nasdaq

Cocrystal Pharma, Inc.

American pharmaceutical preparations company based in Bothell. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Oramed Pharmaceuticals, Sagimet Biosciences Inc. or Magenta Therapeutics, or pick any stock.

  • TickerCOCP on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersBothell, United States2
  • Incorporated inDE3
  • Business address19805 N. Creek Parkway, Bothell, Wa 980113
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300QCJ6RBUJKI7S662
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O Corporation Service Company, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 56448302

See how the biggest companies compare on our leaderboards

(including SARS-CoV-2 & MERS-CoV), respiratory virus infections and hepatitis C virus (“HCV”) infections.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2020

-476.0%Operating margin5
-479.0%Net margin5
-69.3%Revenue growth, 20205
-18.4%Return on equity6
-$10.1MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2020

  • Research and development100¢$6.0M
  • Interest0¢$8.0K

Out of $2.0M in revenue.5 The company lost money this year.

Financial statements

Revenue75$2.0M in 2020−69% since 2019
0$2.0M$4.0M$6.0M$8.0M2019: $6.6M$6.6M20192020: $2.0M$2.0M2020−69%
Operating income75-$9.6M in 2020−80% since 2019
-$60.0M-$40.0M-$20.0M02019: -$48.4M-$48.4M20192020: -$9.6M-$9.6M2020−80%
Net income75-$9.6M in 2020−80% since 2019
-$60.0M-$40.0M-$20.0M02019: -$48.2M-$48.2M20192020: -$9.6M-$9.6M2020−80%

Every line of the income statement as filed: the last 2 fiscal years, latest first.10

Period ending2025-12-312024-12-31
Research and development$5.1M$12.5M
General and administrative$4.0M$5.3M
Total operating expenses$9.0M$17.9M
Loss from operations-$9.0M-$17.9M
Interest income, net$134.0K$537.0K
Foreign exchange gain (loss)$54.0K-$163.0K
Total other income, net$188.0K$374.0K
Net loss-$8.8M-$17.5M
Net loss per common share, basic-$0.78-$1.72
Net loss per common share, diluted-$0.78-$1.72
Weighted average number of common shares outstanding, basic11.3M shares10.2M shares
Weighted average number of common shares outstanding, diluted11.3M shares10.2M shares

Compare Cocrystal Pharma, Inc. with another company

Leadership

Who has led Cocrystal Pharma, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Gary Wilcox2014–2020
  2. Jeffrey A. Meckler2015–2016
  3. James Sapirstein2026–now

Chief financial officer

  1. Gerald A. McGuire2014–2015
  2. Curtis Dale2015
201520202025
Board members and other officers (14)

Former names

  • BIOZONE PHARMACEUTICALS, INC.Mar 31, 2011 to Mar 25, 20143
  • International Surf Resorts, Inc.Sep 20, 2007 to Mar 4, 20113

Timeline

  1. Jun 3, 2026New chief executive James Sapirstein becomes CEO11
  2. Oct 2, 2015New chief executive Jeffrey A. Meckler becomes CEO12
  3. Mar 17, 2014New chief executive Gary Wilcox becomes CEO13

Filings

191 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 81 major events, 49 insider forms, 10 large holders, 30 other. The latest 20:

  1. Sep 9, 20268-K EDGAR
  2. Aug 21, 20263 EDGAR
  3. Aug 18, 20268-K EDGAR
  4. Aug 17, 20268-K EDGAR
  5. Aug 13, 202610-Q EDGAR
  6. Aug 7, 2026SCHEDULE 13D/A EDGAR
  7. Aug 7, 2026SCHEDULE 13D EDGAR
  8. Aug 6, 20264 EDGAR
  9. Aug 5, 20264 EDGAR
  10. Aug 3, 20268-K EDGAR
  11. Jul 17, 20268-K EDGAR
  12. Jun 9, 20268-K EDGAR
  13. Jun 3, 20264 EDGAR
  14. Jun 3, 20263 EDGAR
  15. Jun 3, 20268-K EDGAR
  16. May 27, 2026DEFA14A EDGAR
  17. May 27, 2026DEF 14A EDGAR
  18. May 26, 20268-K EDGAR
  19. May 15, 202610-Q EDGAR
  20. May 1, 2026EFFECT EDGAR

The 191 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

11 open-market trades by officers, directors and large owners since October 2021: 11 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 5, 2026FROST PHILLIP MD ET ALDirectorBuy10,000$0.98$9.8KForm 4
Aug 3, 2026FROST PHILLIP MD ET ALDirectorBuy75,000$0.94$70.5KForm 4
Feb 24, 2026FROST PHILLIP MD ET ALDirectorBuy20,000$1.00$20.0KForm 4
Feb 6, 2026FROST PHILLIP MD ET ALDirectorBuy50,000$0.95$47.5KForm 4
Dec 31, 2025FROST PHILLIP MD ET ALDirectorBuy50,000$0.95$47.5KForm 4
Dec 30, 2025FROST PHILLIP MD ET ALDirectorBuy20,000$0.97$19.4KForm 4
Dec 26, 2025FROST PHILLIP MD ET ALDirectorBuy40,000$0.97$38.8KForm 4
Dec 24, 2025FROST PHILLIP MD ET ALDirectorBuy25,000$0.97$24.2KForm 4
Nov 26, 2025FROST PHILLIP MD ET ALDirectorBuy4,000$0.99$4.0KForm 4
Nov 25, 2025FROST PHILLIP MD ET ALDirectorBuy20,000$0.94$18.8KForm 4
Apr 4, 2023FROST PHILLIP MD ET ALDirectorBuy1,015,229$1.97$2.0MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 28. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC358,228$376.1K0.0%+118,257
Renaissance Technologies LLC179,628$188.6K0.0%+55,700
Two Sigma Investments, LP175,379$184.1K0.0%New
Geode Capital Management, LLC76,208$80.0K0.0%−14,023
BlackRock, Inc.73,746$77.4K0.0%No change
Citadel Advisors LLC45,118$47.4K0.0%New
Neuberger Berman Group LLC31,886$33.5K0.0%No change
XTX Topco Ltd29,342$30.8K0.0%−6,689
Jane Street Group, LLC25,761$27.0K0.0%+13,050
Vanguard Fiduciary Trust Co24,016$25.2K0.0%No change
State Street Corp20,543$21.6K0.0%No change
Parallel Advisors, LLC12,569$13.2K0.0%No change
Northern Trust Corp11,921$12.5K0.0%No change
Ground Swell Capital, LLC10,752$11.3K0.0%New
Wells Fargo & Company/mn6,257$6.6K0.0%−782
UBS Group AG4,133$4.3K0.0%−511
Tower Research Capital LLC (TRC)3,984$4.2K0.0%−264
Morgan Stanley871$9150.0%−77
Northwestern Mutual Wealth Management Co817$8580.0%No change
Clean Yield Group418$4390.0%No change
Nvwm, LLC84$880.0%No change
Barclays PLC42$440.0%New
SBI Securities Co., Ltd.33$350.0%No change
Allied Private Wealth LLC32$310.0%New
Hrt Financial LP20,336$210.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33